Among them, brentuximab vedotin (BV), an antibody-drug conjugate directed against the CD30 antigen, has shown encouraging results in patients with relapsed classical Hodgkin’s lymphoma (cHL) and relapsed anaplastic large cell lymphoma (ALCL) [17]. The gene discussed is TNFRSF8; the disease is classic Hodgkin lymphoma.